BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They presently have a $70.00 price objective on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 152.34% from the stock’s current price. BBIO has […]
Primecap Management Co. CA boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the quarter. Primecap Management […]
Primecap Management Co. CA lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the period. Primecap […]